ArticleThe Journal of clinical investigation2003
Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus.
Article in The Journal of clinical investigation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 143 citations in OpenAlex.
- Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus.Annals of the rheumatic diseases · 2023Article
- Metabolic signatures of immune cells in chronic kidney disease.Expert reviews in molecular medicine · 2022Review
- Mechanism by which the combination of SjCL3 and SjGAPDH protects against Schistosoma japonicum infection.Parasitology research · 2021Article
- Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15.PloS one · 2021Article
- Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome.International journal of molecular sciences · 2019Review
- Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury.International journal of molecular sciences · 2019Review
- α-Lactosylceramide Protects Against iNKT-Mediated Murine Airway Hyperreactivity and Liver Injury Through Competitive Inhibition of Cd1d Binding.Frontiers in chemistry · 2019Article
- Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice.Scientific reports · 2018Article
- Tissue-Resident Lymphocytes in the Kidney.Journal of the American Society of Nephrology : JASN · 2018Review
- Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter.Frontiers in immunology · 2018Review
- Invariant Natural Killer T Cell Subsets-More Than Just Developmental Intermediates.Frontiers in immunology · 2018Review
- Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity.Frontiers in immunology · 2018Review
- Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.Clinical reviews in allergy & immunology · 2017Review
- Invariant natural killer T cells in lupus patients promote IgG and IgG autoantibody production.European journal of immunology · 2015Article
- Immunoregulation of NKT Cells in Systemic Lupus Erythematosus.Journal of immunology research · 2015Review
- The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation.Frontiers in immunology · 2015Review
- The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions.Frontiers in immunology · 2015Review
- Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model.mAbs · 2015Article
- Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice.Journal of autoimmunity · 2014Article
- Mechanisms of innate lymphoid cell and natural killer T cell activation during mucosal inflammation.Journal of immunology research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
In vivo treatment of mice with the natural killer T (NKT) cell ligand, alpha-galactosylceramide (alphaGalCer), ameliorates autoimmune diabetes and experimental autoimmune encephalomyelitis (EAE) by shifting pathogenic Th1-type immune responses to nonpathogenic Th2-type responses. In the current study, in vivo activation of NKT cells in adult NZB/W mice by multiple injections of alphaGalCer induced an abnormal Th1-type immune response as compared with the Th2-type response observed in nonautoimmune C57BL/6 mice. This resulted in decreased serum levels of IgE, increased levels of IgG2a and IgG2a anti-double-stranded DNA (anti-dsDNA) Ab's, and exacerbated lupus. Conversely, treatment of NZB/W mice with blocking anti-CD1d mAb augmented Th2-type responses, increased serum levels of IgE, decreased levels of IgG2a and IgG2a anti-dsDNA Ab's, and ameliorated lupus. While total CD4+ T cells markedly augmented in vitro IgM anti-dsDNA Ab secretion by splenic B cells, the non-CD1d-reactive (CD1d-alphaGalCer tetramer-negative) CD4+ T cells (accounting for 95% of all CD4+ T cells) failed to augment Ab secretion. The CD1d-reactive tetramer-positive CD4+ T cells augmented anti-dsDNA Ab secretion about tenfold. In conclusion, activation of NKT cells augments Th1-type immune responses and autoantibody secretion that contribute to lupus development in adult NZB/W mice, and anti-CD1d mAb might be useful for treating lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.